MX363484B - Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa. - Google Patents

Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa.

Info

Publication number
MX363484B
MX363484B MX2015006533A MX2015006533A MX363484B MX 363484 B MX363484 B MX 363484B MX 2015006533 A MX2015006533 A MX 2015006533A MX 2015006533 A MX2015006533 A MX 2015006533A MX 363484 B MX363484 B MX 363484B
Authority
MX
Mexico
Prior art keywords
novel compounds
diacylglycerol acyltransferase
dgat
acyltransferase inhibitors
inhibitors
Prior art date
Application number
MX2015006533A
Other languages
English (en)
Other versions
MX2015006533A (es
Inventor
Mui Cheung
Raghuram S Tangirala
Original Assignee
Glaxosmithkline Llc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc Star filed Critical Glaxosmithkline Llc Star
Publication of MX2015006533A publication Critical patent/MX2015006533A/es
Publication of MX363484B publication Critical patent/MX363484B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se relaciona con compuestos novedosos que son inhibidores de la acil coenzima A: diacilglicerol aciltransferasa 1 (DGAT-1), con composiciones farmacéuticas que los contienen, con procedimientos para su preparación, y con su uso en terapia, solos o en combinación con terapias de manejo de peso u otras terapias para disminuir triglicéridos, para la prevención o el tratamiento de enfermedades relacionadas con la disfunción de la DGAT-1 o en donde la modulación de la actividad de la DGAT-1 puede tener un beneficio terapéutico.
MX2015006533A 2012-11-23 2013-11-22 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa. MX363484B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3593DE2012 2012-11-23
IN750DE2013 2013-03-14
IN3172DE2013 2013-10-25
PCT/US2013/071376 WO2014081994A1 (en) 2012-11-23 2013-11-22 Novel compounds as diacylglycerol acyltransferase inhibitors

Publications (2)

Publication Number Publication Date
MX2015006533A MX2015006533A (es) 2015-08-06
MX363484B true MX363484B (es) 2019-03-21

Family

ID=50776577

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006533A MX363484B (es) 2012-11-23 2013-11-22 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa.

Country Status (31)

Country Link
US (1) US20150322082A1 (es)
EP (2) EP2922551B1 (es)
JP (1) JP6279600B2 (es)
KR (1) KR102176463B1 (es)
CN (1) CN104918620B (es)
AU (1) AU2013347843B2 (es)
BR (1) BR112015011982A8 (es)
CA (1) CA2892304C (es)
CL (1) CL2015001397A1 (es)
CY (1) CY1121426T1 (es)
DK (1) DK2922551T3 (es)
EA (1) EA031114B1 (es)
ES (1) ES2708626T3 (es)
HK (1) HK1214757A1 (es)
HR (1) HRP20190099T1 (es)
HU (1) HUE042483T2 (es)
IL (1) IL238835B (es)
LT (1) LT2922551T (es)
ME (1) ME03315B (es)
MX (1) MX363484B (es)
NZ (1) NZ630436A (es)
PE (1) PE20150967A1 (es)
PH (1) PH12015501109B1 (es)
PL (1) PL2922551T3 (es)
PT (1) PT2922551T (es)
RS (1) RS58539B1 (es)
SG (1) SG11201503761WA (es)
SI (1) SI2922551T1 (es)
UA (1) UA115079C2 (es)
WO (1) WO2014081994A1 (es)
ZA (1) ZA201503304B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018052818A (ja) * 2015-01-28 2018-04-05 武田薬品工業株式会社 スルホンアミド化合物
BR112019009731A2 (pt) 2016-11-18 2019-08-13 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100795462B1 (ko) * 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2010086820A1 (en) * 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
WO2011121350A1 (en) * 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
SG195044A1 (en) 2011-05-20 2013-12-30 Glaxosmithkline Ip No 2 Ltd Novel compounds as diacylglycerol acyltransferase inhibitors

Also Published As

Publication number Publication date
EA031114B1 (ru) 2018-11-30
SI2922551T1 (sl) 2019-05-31
MX2015006533A (es) 2015-08-06
PH12015501109A1 (en) 2015-08-17
EP2922551A1 (en) 2015-09-30
RS58539B1 (sr) 2019-04-30
BR112015011982A8 (pt) 2019-10-08
JP6279600B2 (ja) 2018-02-14
IL238835A0 (en) 2015-06-30
WO2014081994A1 (en) 2014-05-30
PH12015501109B1 (en) 2015-08-17
AU2013347843A1 (en) 2015-05-28
CY1121426T1 (el) 2020-05-29
CN104918620B (zh) 2017-06-09
JP2016500109A (ja) 2016-01-07
EP3492474B1 (en) 2021-08-11
HUE042483T2 (hu) 2019-06-28
HRP20190099T1 (hr) 2019-04-19
ZA201503304B (en) 2016-05-25
US20150322082A1 (en) 2015-11-12
EP3492474A1 (en) 2019-06-05
CA2892304A1 (en) 2014-05-30
HK1214757A1 (zh) 2016-08-05
IL238835B (en) 2019-07-31
CA2892304C (en) 2021-03-30
LT2922551T (lt) 2019-02-11
PE20150967A1 (es) 2015-06-25
UA115079C2 (uk) 2017-09-11
SG11201503761WA (en) 2015-06-29
PL2922551T3 (pl) 2019-06-28
NZ630436A (en) 2016-08-26
CN104918620A (zh) 2015-09-16
ME03315B (me) 2019-10-20
KR20150087852A (ko) 2015-07-30
ES2708626T3 (es) 2019-04-10
AU2013347843B2 (en) 2016-06-16
EP2922551B1 (en) 2018-10-31
BR112015011982A2 (pt) 2017-07-11
EA201590982A1 (ru) 2015-11-30
KR102176463B1 (ko) 2020-11-09
EP2922551A4 (en) 2016-04-27
DK2922551T3 (en) 2019-02-18
CL2015001397A1 (es) 2015-08-28
PT2922551T (pt) 2019-02-04

Similar Documents

Publication Publication Date Title
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
SG10201810879VA (en) Pharmaceutical compounds
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
PH12016501654A1 (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
IN2013CN01340A (es)
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
MY184553A (en) Novel compounds as diacylglycerol acyltransferase inhibitors
MX2014013752A (es) Inhibidores de nampt.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12014502513A1 (en) Nampt inhibitors
WO2014031933A3 (en) Heterocyclic modulators of hif activity for treatment of disease
IN2015DN01151A (es)
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.